Return to Index
- Delestrogen (injectable)
- DepGynogen (injectable)
- Depo-Estradiol Cypionate (injectable)
- Depogen (injectable)
- Estra-L (injectable)
- Gynogen L.A. (injectable)
- Valergen (injectable)
- and others
Roe D and Campbell T. Drugs and nutrients: The interactive effects. New York, NY: Marcel Dekker; 1984: 479.
Choi YK, Han IK, and Yoon HK. Ipriflavone for the treatment of osteoporosis. Osteoporos Int . 1997;7(Suppl 3):S174-S178.
de Aloysio D, Gambacciani M, Altieri P, et al. Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 1997;11: 289-293.
Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas . 1997;28:75-81.
Melis GB, Paoletti AM, Bartolini R, et al. Ipriflavone and low doses of estrogen in the prevention of bone mineral loss in climacterium. Bone Miner . 1992;19:S49-S56.
Nozaki M, Hashimoto K, et al. Treatment of bone loss in oophorectomized women with a combination of ipriflavone and conjugated equine estrogen. Int J Gyn Ob. 1998;62:69-75.
Petilli M, et al. Interactions between ipriflavone and the estrogen receptor. Calcif Tissue Int. 1995;56:160-165.
Cecchini MG, et al. Ipriflavone inhibits bone resorption in intact and ovariectomized rats. Calcif Tissue Int. 1997;61:S9-S11.
Rivers JM and Devine M. Plasma ascorbic acid concentrations and oral contraceptives. Am J Clin Nutr. 1972;25:684-689.
Pronsky Z, ed. Powers and Moore's food medication interactions. 10th ed. Pottstown, PA: Food-Medication Interactions; 1997: 99.
Nielsen FH, Hunt CD, Mullen LM, Hunt JR. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB J 1987;1:394-397.
Naghii and Samman S. The effect of boron supplementation on its urinary excretion and selected cardiovascular risk factors in healthy male subjects. Biol Trace Elem Res 1997;56:273-286.
Meng Q, Yuan F, Goldberg ID, et al. Indole-3-carbinol is a negative regulator of estrogen receptor-alpha signaling in human tumor cells. J Nutr . 2000;130:2927-293l.
Gehm BD, McAndrews JM, Chien PY, et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA. 1997;94:14138-14143.
Wilbur P. The phyto-oestrogen debate. Eur J Herbal Med. 1196;2:20-26.
Hirata JD, Swiersz LM, Zell B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril. 1997;68:981-986.
Michnovicz JJ. Increased estrogen 2-hydroxylation in obese women using oral indole-3-carbinol. Int J Obes Relat Metab Disord. 1998;22:227-229.
Bradlow HL, Sepkovic DW, Telang NT, et al. Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent. Ann N Y Acad Sci. 1999;889:204-213.
Yuan F, Chen DZ, Liu K, et al. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res. 1999;19:1673-1680.
Zhu BT, Loder DP, Cai MX et al. Dietary administration of an extract from rosemary leaves enhances the liver microsomal metabolism of endogenous estrogens and decreases their uterotropic action in CD-1 mice. Carcinogenesis . 1998;19:1821-1827.
- Reviewer: EBSCO CAM Review Board
- Review Date: 12/2015
- Update Date: 12/15/2015